Browse more cannabis research, findings, methods, and limitations.
Review of CHS management finds standard anti-nausea drugs often fail, while haloperidol and topical capsaicin show promise. Cannabis cessation remains the definitive treatment.
Qualitative analysis of 64 Canadian cannamom social media posts found cannabis positioned as a wellness tool for achieving motherhood ideals, with product marketing embedded in community support narratives.
Study of 202 trauma-exposed cannabis users found THC proportion (not THC:CBD ratio) predicted dependence and anxiety, with no gender differences in this association.
Retrospective study of 29 women with chronic pain found individually tailored full-spectrum cannabis extracts provided pain relief across all patients, with most reducing other medications and reporting broad quality-of-life improvements.
Systematic review of 9 studies found CB2 receptor activation reduced inflammation and bone loss in periodontitis models, with bioinformatics revealing distinct roles for CB1 and CB2 in gum disease.
Survey of 493 Polish students found 31% used marijuana for mental health alongside high rates of other complementary therapies, with marijuana users showing worse depressive symptoms and barriers to professional care driving self-treatment.
National database analysis of 191,315 HPB surgery patients found cannabis use was not associated with worse perioperative complications, with users actually showing lower pneumonia risk.
National database analysis of 907,790 chronic pancreatitis patients found cannabis users had 53% lower mortality, lower ICU admissions, and fewer blood clots, though healthy user bias may explain some findings.
Study of 136 pregnant cannabis users found pandemic-era users were over twice as likely to use cannabis for symptom management, more likely to use edibles, and more likely to report physician involvement.
Meta-analysis of 220,362 adolescents across 47 countries found 7% global cannabis prevalence, with boys and high-income countries showing higher rates and Latin America leading regionally.
Study reveals CBD's anticonvulsant mechanism works through enhancing DEC2's suppression of the SCN2A sodium channel, reducing neuronal excitability and seizure susceptibility in laboratory models.
Review of molecular, clinical, and forensic evidence shows cannabinoids can disturb cardiac electrophysiology and unmask hidden genetic heart rhythm disorders, potentially causing fatal arrhythmias.
Study of 1,017 African American youth found polygenic risk scores for cannabis disorder did not predict cannabis initiation age, and parental monitoring interacted with genetic risk in unexpected ways.
Case report of a 54-year-old woman with 24 years of refractory chronic pancreatitis who achieved substantial pain relief and cessation of acute episodes after starting CBD-rich medical cannabis.
Florida medical cannabis patient survey found low contamination knowledge, 15% reporting suspected contaminated purchases, and 25% purchasing products they were uncomfortable consuming due to quality concerns.
3-year study of 467 first-episode psychosis patients found distinct alcohol and cannabis trajectories: alcohol users maintained use while some cannabis users reduced it, though cannabis reducers still had higher hospitalization rates than abstainers.
Post hoc analysis of two phase 3 CBD trials found that a 31% reduction in drop seizures, not the traditional 50%, was the threshold for caregiver-perceived meaningful improvement in Lennox-Gastaut syndrome.
Analysis of 2,267 young adults identified five cannabis-tobacco use patterns, with the heaviest poly-product users disproportionately representing populations facing substance use disparities.
Case study analysis of cannabis social equity programs in 5 US states found varied approaches to expungements, business assistance, and revenue allocation, with limited evidence of effectiveness.
Study of 2,981 umbilical cord samples found THC positivity increased from 40.6% to 46.2% after Illinois legalized cannabis, with significantly higher THC concentrations in positive samples.
The Cochrane Review's second update confirms: no medication has strong evidence for treating cannabis use disorder or reliably reducing withdrawal symptoms.
Survey of 1,402 tobacco retailers found THC and CBD each available in about 10% of stores across three US cities, with e-cigarette and cigar stores most likely to carry cannabinoids regardless of local cannabis policy.
Survey of 3,389 cannabis users found those who first used for self-medication consumed more THC and had worse mental health than those who started for social reasons, suggesting initial motivation predicts later outcomes.
Health assessments of 710 Aboriginal and Torres Strait Islander youth found 72% were not depressed, with absence of marijuana use among key protective factors alongside exercise, sport, and absence of other adversities.
UK registry study of 148 fibromyalgia patients found cannabis products improved anxiety, sleep, symptom severity, and quality of life over 12 months, with no differences between oils and dried flower formulations.
Mixed-methods study of 124 Thai chronic disease patients found most used cannabis tea daily as complementary medicine for diabetes or hypertension, but only 35% knew about potential drug interactions.
20-year analysis of German addiction treatment data found cannabis-related admissions nearly tripled (7.1% to 19.9%), with patients getting older and less likely to be first-time treatment seekers.
Study of 115 mother-infant pairs found prenatal cannabis exposure alone did not affect newborn behavior, but cannabis-exposed infants from low-income households showed reduced attention and heightened arousal.
4-week microrandomized trial of 53 young adults found neither mindfulness nor distraction text messages reduced cannabis craving at the moment it was experienced, despite excellent intervention engagement.
Experiment with 431 cannabis users found CBD labels perceived as safest and most beneficial but least desired for purchase, while visual potency aids did not influence perceptions.
Lab study found the CB2 agonist JWH-133 reduced HIV replication in both macrophages and microglia with distinct cell-type-specific anti-inflammatory mechanisms, suggesting CB2 as a target for HIV-associated neuroinflammation.
6-month prospective study of 69 MS patients found vaporized CBD/THC (13%/9%) significantly improved disability scores, muscle spasticity, and bladder dysfunction.
Study of 195 Colorado cannabis users found frequent use associated with higher anxiety but not depression, with similar rates of prescription medication use across all groups.
Survey of 2,476 high schoolers found cannabis vaping more prevalent among LGB+, Hispanic, and multiethnic adolescents, with dual nicotine-cannabis vapers showing the worst mental health and behavioral profiles.
Double-blind RCT of 53 participants with severe cerebral palsy found no benefit of full-spectrum cannabis oil (10:1 CBD:THC) over placebo for spasticity, motor function, or quality of life, though the product was well-tolerated.
Longitudinal sibling study of 1,261 high-risk adolescents found cannabis use was not associated with suicidal thoughts or behaviors after controlling for shared genetic and environmental influences.
Analysis of national insurance data examined whether recreational cannabis legalization changed opioid and non-opioid pain prescriptions, providing real-world evidence on cannabis-opioid substitution.
Study found cannabis users and non-users responded differently to anti-cannabis campaign messages, suggesting prevention and harm reduction campaigns may need distinct approaches for each audience.
Analysis of 120,691 treatment observations from 16,395 medical cannabis patients found symptom relief decreased 0.5% per session due to tolerance, with patients compensating by increasing dose but not THC potency.
Review of CHS highlights frequent misdiagnosis, ineffectiveness of standard anti-nausea drugs, characteristic relief from hot water bathing, and the essential role of cannabis cessation in resolution.
Review finds cannabinoids may complement atopic dermatitis treatment by targeting skin barrier function, inflammation, and itching through the endocannabinoid system, though clinical evidence remains limited.
Meta-analysis of 24 studies found cannabis use associated with 29% higher risk of acute coronary syndrome, 20% higher stroke risk, and 2.1-fold higher cardiovascular death risk.
Qualitative interviews with 33 Dutch non-prescribed cannabis users identified cost, limited products, physician barriers, and stigma as reasons patients avoid the 20+ year old medical cannabis program.
Survey of Dutch self-medicating cannabis users confirmed most bypass the 20+ year prescribed system, documenting use patterns, motivations, and barriers to formal access.
Case report of a 28-year-old with Tourette syndrome and ADHD found medical cannabis treatment did not impair driving fitness, contributing to evidence on tolerance and driving safety.
Crossover trial of 20 adults found CBD co-administration increased THC's subjective high, impairment, and blood concentrations, while caffeine had minimal effects on THC outcomes.
Review of comorbid cannabis use and mood disorders in adolescents found bidirectional reinforcement during a critical developmental period, requiring integrated assessment and treatment approaches.
German multicenter chart review of 202 epilepsy patients found adjunctive CBD achieved 43-44% responder rates at 3 and 12 months, with seizure days dropping from 30 to 18 per month and 67% remaining on treatment at 1 year.
German real-world study of 126 patients found CBD plus clobazam achieved 48% seizure response at 3 months for LGS/DS, with 63% tonic-clonic response and 70% treatment retention at 1 year.
Study of 104 adults found cannabis users with ADHD reported subjective symptom improvement after acute use, but chronic cannabis use was associated with objective cognitive differences regardless of ADHD status.